β-defensin 30 inhibitors are molecules that specifically target and suppress the activity of β-defensin 30, a member of the defensin family of antimicrobial peptides. Defensins are small, cysteine-rich peptides known for their ability to modulate immune responses and influence the structural integrity of cellular membranes. β-defensin 30, in particular, is characterized by its ability to interact with cellular membranes and participate in various biological processes involving host defense mechanisms. The inhibitors of this peptide typically function by binding to β-defensin 30 or its interaction sites, thereby reducing its biological activity. Structurally, β-defensin 30 inhibitors can vary significantly depending on their origin, with some being small organic molecules, others being peptides or proteins, and still others arising from synthetic chemistry approaches. Their efficacy is often influenced by their ability to precisely target the β-defensin 30 domain without affecting other defensins, ensuring a selective inhibition process.
From a biochemical standpoint, the interactions between β-defensin 30 and its inhibitors are often mediated by hydrogen bonding, hydrophobic interactions, and electrostatic forces, given the charged nature of defensins and their interaction sites. The selective nature of β-defensin 30 inhibitors is crucial, as this peptide is involved in the regulation of various intracellular pathways, which require careful modulation to prevent unwanted biological outcomes. Various techniques, including high-throughput screening, computational modeling, and structural analysis, are used to identify and optimize these inhibitors. Furthermore, studies on these inhibitors often involve elucidating the conformational changes that occur upon binding, as well as determining their binding affinities through biophysical methods like isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR). Understanding the molecular mechanisms by which β-defensin 30 inhibitors operate is crucial for expanding knowledge of their role in regulating defensin-related biological processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $178.00 $270.00 $712.00 | 3 | |
PARP inhibitor disrupting DNA repair. Veliparib indirectly inhibits β-defensin 30 by interfering with the DNA damage response pathway, impacting the regulation of β-defensin 30 transcription under conditions of cellular stress. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor disrupting the PI3K/AKT pathway. LY294002 indirectly hampers β-defensin 30, as PI3K/AKT signaling is implicated in the regulation of β-defensin 30 transcription by modulating specific transcription factors. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
JAK inhibitor targeting JAK-STAT signaling. Ruxolitinib indirectly suppresses β-defensin 30, as the JAK-STAT pathway regulates the transcription of β-defensin 30 by activating STAT proteins. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Calcineurin inhibitor affecting the NFAT pathway. Cyclosporin A indirectly inhibits β-defensin 30 by blocking NFAT activation, a key regulator of β-defensin 30 transcription in response to various stimuli. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor influencing the MAPK/ERK pathway. Trametinib indirectly influences β-defensin 30 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 30 transcription through specific downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hinders β-defensin 30, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 30. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
HDAC inhibitor modulating chromatin structure. Vorinostat indirectly suppresses β-defensin 30 by altering histone acetylation, influencing the accessibility of the β-defensin 30 gene for transcription. | ||||||
Quinomycin A | 512-64-1 | sc-202306 | 1 mg | $163.00 | 4 | |
HIF-1α inhibitor affecting the hypoxia pathway. Echinomycin indirectly suppresses β-defensin 30, as HIF-1α enhances β-defensin 30 transcription under hypoxic conditions, and inhibiting HIF-1α disrupts this regulatory mechanism. | ||||||
Eprosartan | 133040-01-4 | sc-207631 | 10 mg | $166.00 | 1 | |
TLR4 inhibitor affecting the TLR4 signaling pathway. CLI-095 indirectly hampers β-defensin 30, as TLR4 activation is known to upregulate β-defensin 30 expression through NF-κB and AP-1 signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor influencing the mTORC1 pathway. Rapamycin indirectly inhibits β-defensin 30 by modulating mTORC1 signaling, which is implicated in the regulation of β-defensin 30 through control of translation initiation. |